share_log

Insiders Of Gossamer Bio Are Up 38% On Their US$1.27m Purchase

Insiders Of Gossamer Bio Are Up 38% On Their US$1.27m Purchase

Gossamer Bio的内部人士在127万美元的收购中上涨了38%
Simply Wall St ·  03/01 05:32

Gossamer Bio, Inc. (NASDAQ:GOSS) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 22%, resulting in a US$56m rise in the company's market capitalisation, translating to a gain of 38% on their initial investment. As a result, the stock they originally bought for US$1.27m is now worth US$1.74m.

在过去一年中购买股票的Gossamer Bio, Inc.(纳斯达克股票代码:GOSS)内部人士上周获得了丰厚的回报。该股上涨了22%,导致该公司的市值增长了5600万美元,这意味着他们的初始投资收益了38%。结果,他们最初以127万美元的价格购买的股票现在价值174万美元。

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

尽管在长期投资中,内幕交易并不是最重要的事情,但逻辑要求你应该注意内部人士是在买入还是卖出股票。

The Last 12 Months Of Insider Transactions At Gossamer Bio

Gossamer Bio 过去 12 个月的内幕交易

Over the last year, we can see that the biggest insider purchase was by Co-Founder Faheem Hasnain for US$1.0m worth of shares, at about US$1.20 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$1.41. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

在过去的一年中,我们可以看到,最大的内幕收购是联合创始人Faheem Hasnain以每股约1.20美元的价格收购了价值100万美元的股票。尽管我们希望看到内幕买盘,但我们注意到此次大宗收购远低于最近的1.41美元价格。尽管这确实表明内部人士认为该股在较低的价格下被低估,但这笔交易并没有告诉我们他们对当前价格的看法。

Happily, we note that in the last year insiders paid US$1.3m for 1.23m shares. But they sold 22.97k shares for US$26k. In the last twelve months there was more buying than selling by Gossamer Bio insiders. Their average price was about US$1.03. It is certainly positive to see that insiders have invested their own money in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

令人高兴的是,我们注意到,去年内部人士支付了130万美元购买了123万股股票。但他们以2.6万美元的价格出售了22.97万股股票。在过去的十二个月中,Gossamer Bio内部人士的买入量多于卖出量。他们的平均价格约为1.03美元。看到内部人士将自己的资金投资于该公司,这无疑是积极的。但是,您应该记住,他们在股价明显低于今天的水平时买入。您可以看到下图所示的去年的内幕交易(公司和个人)。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!

insider-trading-volume
NasdaqGS:GOSS Insider Trading Volume March 1st 2024
纳斯达克GS: GOSS 内幕交易量 2024 年 3 月 1 日

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

内部人士总是会买入很多股票。因此,如果这适合你的风格,你可以逐一查看每只股票,也可以看看这份免费的公司名单。(提示:业内人士一直在购买它们)。

Insider Ownership

内部所有权

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Insiders own 3.0% of Gossamer Bio shares, worth about US$9.1m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.

测试公司领导者与其他股东之间一致性的另一种方法是查看他们拥有多少股份。我们通常希望看到相当高的内部所有权。根据我们的数据,内部人士拥有Gossamer Bio3.0%的股份,价值约910万美元。虽然总比没有好,但这些持股并没有给我们留下太深的印象。

So What Does This Data Suggest About Gossamer Bio Insiders?

那么这些数据对Gossamer Bio内部人士有什么启示呢?

The fact that there have been no Gossamer Bio insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. We'd like to see bigger individual holdings. However, we don't see anything to make us think Gossamer Bio insiders are doubting the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For instance, we've identified 4 warning signs for Gossamer Bio (2 are a bit unpleasant) you should be aware of.

最近没有Gossamer Bio的内幕交易这一事实肯定不会打扰我们。但是,在过去的一年中,内部人士对该股表现出了更大的兴趣。我们希望看到更多的个人持股。但是,我们认为没有任何东西可以让我们认为Gossamer Bio内部人士对该公司表示怀疑。虽然我们喜欢了解内部人士的所有权和交易情况,但在做出任何投资决策之前,我们一定要考虑股票面临的风险。例如,我们已经确定了你应该注意的Gossamer Bio的4个警告信号(其中2个有点不愉快)。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发